These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32034212)

  • 1. Exploring resveratrol dimers as virulence blocking agents - Attenuation of type III secretion in Yersinia pseudotuberculosis and Pseudomonas aeruginosa.
    Sundin C; Zetterström CE; Vo DD; Brkljača R; Urban S; Elofsson M
    Sci Rep; 2020 Feb; 10(1):2103. PubMed ID: 32034212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa.
    Zetterström CE; Hasselgren J; Salin O; Davis RA; Quinn RJ; Sundin C; Elofsson M
    PLoS One; 2013; 8(12):e81969. PubMed ID: 24324737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors.
    Lam H; Schwochert J; Lao Y; Lau T; Lloyd C; Luu J; Kooner O; Morgan J; Lokey S; Auerbuch V
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Protein-Protein Interface Inhibitors Allow Efficient Inhibition of Type III Secretion Machinery and
    Ngo TD; Plé S; Thomas A; Barette C; Fortuné A; Bouzidi Y; Fauvarque MO; Pereira de Freitas R; Francisco Hilário F; Attrée I; Wong YS; Faudry E
    ACS Infect Dis; 2019 Nov; 5(11):1843-1854. PubMed ID: 31525902
    [No Abstract]   [Full Text] [Related]  

  • 5. Solving the supply of resveratrol tetramers from Papua New Guinean rainforest anisoptera species that inhibit bacterial type III secretion systems.
    Davis RA; Beattie KD; Xu M; Yang X; Yin S; Holla H; Healy PC; Sykes M; Shelper T; Avery VM; Elofsson M; Sundin C; Quinn RJ
    J Nat Prod; 2014 Dec; 77(12):2633-40. PubMed ID: 25405587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An NF-κB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system.
    Duncan MC; Wong WR; Dupzyk AJ; Bray WM; Linington RG; Auerbuch V
    Antimicrob Agents Chemother; 2014; 58(2):1118-26. PubMed ID: 24295981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms.
    Anantharajah A; Buyck JM; Sundin C; Tulkens PM; Mingeot-Leclercq MP; Van Bambeke F
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.
    Kauppi AM; Nordfelth R; Uvell H; Wolf-Watz H; Elofsson M
    Chem Biol; 2003 Mar; 10(3):241-9. PubMed ID: 12670538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron availability and oxygen tension regulate the Yersinia Ysc type III secretion system to enable disseminated infection.
    Hooker-Romero D; Mettert E; Schwiesow L; Balderas D; Alvarez PA; Kicin A; Gonzalez AL; Plano GV; Kiley PJ; Auerbuch V
    PLoS Pathog; 2019 Dec; 15(12):e1008001. PubMed ID: 31869388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.
    Lam HN; Lau T; Lentz A; Sherry J; Cabrera-Cortez A; Hug K; Lalljie A; Engel J; Lokey RS; Auerbuch V
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0169020. PubMed ID: 33875435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic
    Morgan JM; Lam HN; Delgado J; Luu J; Mohammadi S; Isberg RR; Wang H; Auerbuch V
    Front Cell Infect Microbiol; 2018; 8():404. PubMed ID: 30524970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Structure-Function-Inhibition Analysis of the
    Moir DT; Bowlin NO; Berube BJ; Yabut J; Mills DM; Nguyen GT; Aron ZD; Williams JD; Mecsas J; Hauser AR; Bowlin TL
    J Bacteriol; 2020 Aug; 202(18):. PubMed ID: 32601072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Type Three Secretion System in Pseudomonas aeruginosa.
    Anantharajah A; Mingeot-Leclercq MP; Van Bambeke F
    Trends Pharmacol Sci; 2016 Sep; 37(9):734-749. PubMed ID: 27344210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary Hemochromatosis Predisposes Mice to Yersinia pseudotuberculosis Infection Even in the Absence of the Type III Secretion System.
    Miller HK; Schwiesow L; Au-Yeung W; Auerbuch V
    Front Cell Infect Microbiol; 2016; 6():69. PubMed ID: 27446816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.
    Aiello D; Williams JD; Majgier-Baranowska H; Patel I; Peet NP; Huang J; Lory S; Bowlin TL; Moir DT
    Antimicrob Agents Chemother; 2010 May; 54(5):1988-99. PubMed ID: 20176902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased plasmid copy number is essential for Yersinia T3SS function and virulence.
    Wang H; Avican K; Fahlgren A; Erttmann SF; Nuss AM; Dersch P; Fallman M; Edgren T; Wolf-Watz H
    Science; 2016 Jul; 353(6298):492-5. PubMed ID: 27365311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.
    Berube BJ; Murphy KR; Torhan MC; Bowlin NO; Williams JD; Bowlin TL; Moir DT; Hauser AR
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807906
    [No Abstract]   [Full Text] [Related]  

  • 18. Resveratrol oligomers inhibit biofilm formation of Escherichia coli O157:H7 and Pseudomonas aeruginosa.
    Lee JH; Kim YG; Ryu SY; Cho MH; Lee J
    J Nat Prod; 2014 Jan; 77(1):168-72. PubMed ID: 24456071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TpiA is a Key Metabolic Enzyme That Affects Virulence and Resistance to Aminoglycoside Antibiotics through CrcZ in Pseudomonas aeruginosa.
    Xia Y; Wang D; Pan X; Xia B; Weng Y; Long Y; Ren H; Zhou J; Jin Y; Bai F; Cheng Z; Jin S; Wu W
    mBio; 2020 Jan; 11(1):. PubMed ID: 31911486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piericidin A1 Blocks
    Morgan JM; Duncan MC; Johnson KS; Diepold A; Lam H; Dupzyk AJ; Martin LR; Wong WR; Armitage JP; Linington RG; Auerbuch V
    mSphere; 2017; 2(1):. PubMed ID: 28217742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.